A PET [positron emission tomography] study using [11C] GSK189254 to establish the dose, plasma concentration and brain receptor occupancy relationship of GSK239512, a histamine H3 antagonist, in healthy subjects.

Trial Profile

A PET [positron emission tomography] study using [11C] GSK189254 to establish the dose, plasma concentration and brain receptor occupancy relationship of GSK239512, a histamine H3 antagonist, in healthy subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Mar 2014

At a glance

  • Drugs GSK 239512 (Primary)
  • Indications Dementia
  • Focus Pharmacokinetics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 01 Jun 2012 Inclusion and exclusion criteria amended as reported by ClinicalTrials.gov.
    • 27 Oct 2008 Actual end date changed from Apr 2008 to Mar 2008 as reported by Clinicaltrials.gov.
    • 15 Oct 2008 Actual start date changed from Feb 2007 to Mar 2007 as reported by Clinicaltrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top